Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions

被引：0
|
作者：
Mark H. Rozenbaum
Erica Chilson
Raymond Farkouh
Liping Huang
Alejandro Cane
Adriano Arguedas
Maria J. Tort
Vincenza Snow
Ahuva Averin
Derek Weycker
Dhwani Hariharan
Mark Atwood
机构：
[1] Pfizer Inc.,Value and Evidence Team, Pneumococcal Vaccines
[2] Pfizer Inc.,undefined
[3] Avalere Health,undefined
来源：
Infectious Diseases and Therapy | 2024年 / 13卷
关键词：
Children; Costs and cost analysis; Immunization; Pneumonia; Vaccination; Vaccines; Conjugate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：745 / 760
页数：15
相关论文
共 50 条
  • [1] Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions
    Rozenbaum, Mark H.
    Chilson, Erica
    Farkouh, Raymond
    Huang, Liping
    Cane, Alejandro
    Arguedas, Adriano
    Tort, Maria J.
    Snow, Vincenza
    Averin, Ahuva
    Weycker, Derek
    Hariharan, Dhwani
    Atwood, Mark
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (04) : 745 - 760
  • [2] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants
    Rozenbaum, Mark H.
    Huang, Liping
    Perdrizet, Johnna
    Cane, Alejandro
    Arguedas, Adriano
    Hayford, Kyla
    Tort, Maria J.
    Chapman, Ruth
    Dillon-Murphy, Desmond
    Snow, Vincenza
    Chilson, Erica
    Farkouh, Raymond A.
    VACCINE, 2024, 42 (03) : 573 - 582
  • [3] Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
    Rey-Ares, Lucila
    Averin, Ahuva
    Mac Mullen, Mercedes
    Hariharan, Dhwani
    Atwood, Mark
    Carballo, Carolina
    Huang, Liping
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (06) : 1235 - 1251
  • [4] Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany
    Kuehne, Felicitas
    Achtert, Katharina
    Pueschner, Franziska
    Urbanski-Rini, Dominika
    Schiller, Juliane
    Mahar, Ernestine
    Friedrich, Josephine
    Atwood, Mark
    Sprenger, Ralf
    Vietri, Jeffrey
    von Eiff, Christof
    Theilacker, Christian
    EXPERT REVIEW OF VACCINES, 2023, 22 (01) : 921 - 932
  • [5] COST-EFFECTIVENESS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN MEXICAN ADULTS POPULATION
    Huerta, J. L.
    Ta, A.
    Freigofaite, D.
    Torres, G., I
    Wannaadisai, W.
    Huang, L.
    VALUE IN HEALTH, 2024, 27 (06) : S68 - S68
  • [6] COST-EFFECTIVENESS ASSESSMENT OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HONG KONG
    Huang, L.
    Shami, J.
    Georgiou, T.
    Wong, V
    Wong, C.
    VALUE IN HEALTH, 2023, 26 (12) : S198 - S199
  • [7] Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
    Polistena, Barbara
    Icardi, Giancarlo
    Orsi, Andrea
    Spandonaro, Federico
    Di Virgilio, Roberto
    d'Angela, Daniela
    VACCINES, 2022, 10 (12)
  • [8] COST-EFFECTIVENESS OF THE 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE VS 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR A./ULTS IN ARGENTINA
    Mac Mullen, M.
    Carballo, C.
    Seyahian, E.
    VALUE IN HEALTH, 2022, 25 (12) : S132 - S132
  • [9] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
    Malene, B. Mikkelsen
    Oyvind, Husby
    Tor, Molden
    David, N. Mwaura
    Jens, Olsen
    Nanna, V. Kristensen
    Jeffrey, Vietri
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [10] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
    Mikkelsen Malene B
    Husby Oyvind
    Molden Tor
    Mwaura David N
    Olsen Jens
    Kristensen Nanna V
    Vietri Jeffrey
    Cost Effectiveness and Resource Allocation, 21
12345